Dulaglutide, another long-acting GLP-1R agonist, has been shown to significantly reduce LFC and γ-glutamyl transpeptidase levels in patients with T2DM and MASLD [74]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.